一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Cardiology Research >>article

Cardiology Research

IF: 1.39
Download PDF

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.

Published:1 April 2013 DOI: 10.4021/cr270w PMID: 28352420
Hua Ling,?John T Luoma,?Daniel Hilleman

Abstract

Fenofibrate is a third-generation fibric acid derivative indicated as a monotherapy to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B; to increase high-density lipoprotein cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia; and to reduce triglycerides in patients with severe hypertriglyceridemia. In this review, the key characteristics of available fenofibrate formulations are examined. A literature search was conducted, focusing on comparative studies examining bioavailability, food effects, absorption, and lipid efficacy. Fenofibrate is highly lipophilic, virtually insoluble in water, and poorly absorbed. Coadministration with meals was necessary to maximize bioavailability of early formulations. Micronized and nanoparticle formulations of fenofibrate with reduced particle sizes were developed, resulting in greater solubility, improved bioavailability, and in some cases, the ability to be given irrespective of food. A recently introduced hydrophilic choline salt of fenofibric acid also can be taken without regard to meals, is absorbed throughout the gastrointestinal tract, has the highest bioavailability among marketed formulations, and is approved for coadministration with a statin. Differences in bioavailability of fenofibrate formulations have resulted in low-dose (40 - 67) mg and standard-dose (120 - 200 mg) formulations. Different formulations are not equivalent on a milligram-to-milligram basis. In order to prevent medication errors, resulting in underdosing or overdosing with attendant consequences, it is important for healthcare providers to recognize that the formulations of fenofibrate and fenofibric acid that are currently available vary substantially in relation to food effect, equivalency on a milligram-to-milligram basis, and indication to be coadministered with a statin.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Fenofibrate 49562-28-9 C20H21ClO4 784 suppliers $5.00-$602.00
Fenofibric acid 42017-89-0 C17H15ClO4 460 suppliers $5.00-$1500.00
CHOLINE 62-49-7 C5H14NO 91 suppliers $505.54-$505.54

Similar articles

IF:5.4

Desonide: a review of formulations, efficacy and safety.

ACS Applied Energy Materials Nr Kahanek, Cg Gelbard,etc Published: 1 July 2008
万源市| 高陵县| 龙山县| 洛隆县| 垫江县| 五常市| 安庆市| 玉门市| 岚皋县| 梅河口市| 郯城县| 永新县| 滁州市| 湖北省| 南安市| 凉城县| 页游| 砀山县| 斗六市| 陵水| 颍上县| 驻马店市| 乡宁县| 公安县| 德令哈市| 文成县| 漠河县| 大田县| 华坪县| 福建省| 永平县| 南阳市| 璧山县| 黄陵县| 上饶县| 闵行区| 历史| 久治县| 余庆县| 和田市| 阿勒泰市|